Market Place
Sourcing Support
Replay wins IND clearance for PRAME T cell cancer therapy
01 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Replay, MDA IND Cleared for PRAME TCR-NK Cell Therapy
30 Apr 2024 //
GLOBENEWSWIRE
Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy
11 Mar 2024 //
GLOBENEWSWIRE
Syena announce agreement with National Institutes of Health
18 Dec 2023 //
GLOBENEWSWIRE
Syena and Miltenyi enter into GMP agreement for PRAME TCR-NK cell therapy
18 Dec 2023 //
GLOBENEWSWIRE
Replay announces partnership between product company Syena and JURA Bio
21 Sep 2023 //
GLOBENEWSWIRE
Replay and MD Anderson announce FDA clearance of IND application for TCR-NK
24 Jul 2023 //
GLOBENEWSWIRE
Replay and MD Anderson announce FDA clearance of IND application
20 Jun 2023 //
GLOBENEWSWIRE
Cristian Massacesi, M.D., Appointed to Replay Board of Directors
25 May 2023 //
GLOBENEWSWIRE
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
18 May 2023 //
GLOBENEWSWIRE
KKR-backed Replay and MD Anderson form new product company Syena
14 Feb 2023 //
GLOBENEWSWIRE
Replay, MD Anderson form near-clinical TCR-NK cell therapy firm
14 Feb 2023 //
FIERCE BIOTECH
Replay targets genetic brain disorders with new gene therapy company, Kaleibe
14 Dec 2022 //
GLOBENEWSWIRE
Replay receives $1.5 million grant for its hypoimmunogenic technology platform
28 Nov 2022 //
GLOBENEWSWIRE
Replay launches big DNA HSV gene therapy company, Telaria
21 Nov 2022 //
GLOBENEWSWIRE
Replay launches gene therapy spinout Eudora, putting ‘hub-and-spoke’ plans
01 Nov 2022 //
BIOPHARMADIVE
Replay establishes distinguished Scientific Advisory Board of genomic medicine
17 Oct 2022 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.